# A Study to Evaluate LB1410 in Combination With LB4330 in Patients With Advanced or Metastatic Solid Tumors

Source: https://onco.cc/trials/nct06468358/  
OnCo record `nct06468358` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of LB1410 and LB4330 in advanced solid tumours, run by L & L Bio Co., Ltd., Ningbo, China, now recruiting.

## Summary

A Study to Evaluate LB1410 in Combination With LB4330 in Patients With Advanced or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT06468358 by L & L Bio Co., Ltd., Ningbo, China, with 194 participants planned, started 2024-06-19 and due to reach its primary completion in 2026-12-30. Interventions recorded: LB1410 and LB4330.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06468358
- Phase: 1/2
- Setting: A Phase Ib/II, Open, Dose-escalation and Expansion Study to Evaluate LB1410 in Combination With LB4330 in Patients With Advanced or Metastatic Solid Tumors
- Sponsor: L & L Bio Co., Ltd., Ningbo, China
- Enrolled: 194

## Sources

- ClinicalTrials.gov NCT06468358: https://clinicaltrials.gov/study/NCT06468358

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [LB1410](https://onco.cc/drugs/lb1410/), [LB4330](https://onco.cc/drugs/lb4330/)

---
JSON: https://onco.cc/api/v1/entities/nct06468358.json